Krabbe disease

Last updated
Krabbe disease
Other names
  • Globoid cell leukodystrophy
  • Galactosylceramide lipidosis
  • GALC deficiency
  • Galactocerebrosidase deficiency
Globoid cell leukodystrophy PAS.jpg
A histopathology slide of a brain with Krabbe disease showing giant cells with PAS stain inclusions ("globoid cells") within astrocytic gliosis and loss of myelinated fibers.
Specialty Metabolic disorder   OOjs UI icon edit-ltr-progressive.svg
Symptoms
[1]
Usual onsetWithin 3 to 6 months of birth, but can present in childhood or even adulthood
TypesInfantile, juvenile and adult
CausesMutation of GALC gene
Risk factors Parents who are heterozygous (only one copy) for the mutation to the GALC gene
Diagnostic method Histopathology, genetic testing [1]
Prevention Prenatal diagnosis and screening of at-risk couples [1]
Treatment Symptomatic and supportive treatment only, but stem cell transplantation may be beneficial [1]
Prognosis One-, two-, and three-year survival rates of 60%, 26%, and 14%, respectively [2]

Krabbe disease (KD) (also known as globoid cell leukodystrophy [3] or galactosylceramide lipidosis) is a rare and often fatal lysosomal storage disease that results in progressive damage to the nervous system. KD involves dysfunctional metabolism of sphingolipids and is inherited in an autosomal recessive pattern. The disease is named after the Danish neurologist Knud Krabbe (1885–1961). [4]

Contents

Signs and symptoms

Symptoms in asymptomatic infantile-onset (<12 months after birth) and later-onset Krabbe disease present themselves differently. Of individuals with infantile-onset Krabbe disease, 85–90% display progressive neurologic deterioration in infancy and death before the age of two. [5] Symptoms include irritability, fevers, limb stiffness, seizures, feeding difficulties (like GERD), vomiting, staring episodes, and slowing of mental and motor development. In the first stages of the disease, doctors often mistake the symptoms for those of cerebral palsy. Other symptoms include muscle weakness, spasticity, deafness, optic atrophy, optic nerve enlargement, [6] blindness, paralysis, and difficulty when swallowing. Prolonged weight loss may also occur.[ citation needed ]

10–15% of individuals with later-onset Krabbe disease have a much slower disease progression. These individuals may also display symptoms such as esotropia, slurred speech, and slow development or loss of motor milestones. [5]

Causes

Autosomal recessive inheritance pattern as seen in Krabbe disease Autosomal recessive - en.svg
Autosomal recessive inheritance pattern as seen in Krabbe disease

Krabbe disease is caused by mutations in the GALC gene located on chromosome 14 (14q31), [7] which is inherited in an autosomal recessive manner. Mutations in the GALC gene cause a deficiency of an enzyme called galactosylceramidase. [8] In rare cases, it may be caused by a lack of active saposin A (a derivative of prosaposin). [1]

The buildup of unmetabolized lipids adversely affects the growth of the nerve's protective myelin sheath (the covering that insulates many nerves) resulting in demyelination and severe progressive degeneration of motor skills. As part of a group of disorders known as leukodystrophies, Krabbe disease results from the imperfect growth and development of myelin.[ citation needed ]

Galactosylceramidase deficiency also results in a buildup of a glycosphingolipid called psychosine, which is toxic to oligodendrocytes, a type of non-neuronal cell found in the nervous system, collectively termed neuroglia. [9]

Diagnosis

There are a few ways to help pinpoint the presence of Krabbe disease. Newborn screening for Krabbe disease includes assaying dried blood cells for GALC enzyme activity and molecular analysis for evidence of GALC enzyme mutations. Infants displaying low enzyme activity and/or enzyme mutations should be referred for additional diagnostic testing and neurological examination. [10] 0-5% GALC enzyme activity is observed in all symptomatic individuals with Krabbe disease. [5] High concentration of psychosine in dried blood spots may also be identified as a marker for Krabbe disease. [11] A 2011 study discovered that individuals with Krabbe disease, more so in later-onset individuals, tend to have an abnormal increase in CSF protein concentration. [12]

The disease may be diagnosed by its characteristic grouping of certain cells (multinucleated globoid cells), nerve demyelination and degeneration, and destruction of brain cells. Special stains for myelin (e.g., luxol fast blue) may be used to aid diagnosis[ citation needed ].

New York, [13] Missouri and Kentucky [14] include Krabbe in the newborn screening panel. [15] Indiana started screening in 2020. [16]

Treatment

Although there is no known cure for Krabbe disease, bone marrow transplantation or hematopoietic stem cell transplantation (HSCT) has been shown to benefit cases early in the course of the disease. Generally, treatment for the disorder is symptomatic and supportive. Physical therapy may help maintain or increase muscle tone and circulation.[ citation needed ]

A 15-year study on the developmental outcomes of children with Krabbe disease who underwent HSCT in the first seven weeks after birth found that patients have a better prognosis for both lifespan and functionality, with a slower progression of the disease. [17] Even symptomatic individuals with later-onset Krabbe disease may benefit from HSCT if diagnosed early enough. [18] Umbilical-cord blood is typically used as the source for the transplant stem cells. [19] Clinical trials for gene therapy are currently enrolling patients. [20]

Management

Symptom management can be particularly difficult for individuals with infantile onset, as symptoms tend to progress rapidly. [19] Because there is no treatment for Krabbe disease, management of the condition is typically supportive and aimed at alleviating symptoms. Frequent evaluation is encouraged in order to anticipate the onset of, and preparation for, certain symptoms. [5] Physical therapy can help to alleviate motor difficulties and increase strength, mobility, and flexibility. [5]

Gastrostomy tubes are used to circumvent feeding difficulties and prevent aspiration. A simultaneous gastrostomy tube insertion and Nissen fundoplication procedure is commonly performed to prevent the need for a secondary surgical procedure. [19] Individuals with Krabbe disease with severe motor deficits tend to be more susceptible to overfeeding, as they require less calorie consumption and thus consume fewer calories than what caretakers may expect. [19] There is also evidence that routine vaccines may accelerate disease progression; many individuals with Krabbe disease tend to not follow traditional vaccination procedures. [19]

Prognosis

In infantile Krabbe disease, death usually occurs in early childhood. A 2011 study found one-, two-, and three-year survival rates of 60%, 26%, and 14%, respectively, with a few surviving longer. Patients with late-onset Krabbe disease tend to have a slower progression of the disease and live significantly longer. [2]

Epidemiology

This disease does not only impact humans, but other animals such as monkeys, mice, and dogs have been observed to develop Krabbe disease as well. While certain gene deletions are more frequent than others, novel mutations resulting in Krabbe disease have been discovered worldwide. Most commonly, the underlying cause of the disease is a deletion of a GALC gene, which causes a deficiency in the GALC enzyme. This is the circumstance in 80% of patients who have European and Mexican origins. [21] The mortality rate of early infantile Krabbe disease is 90% before the age of two. Later onset of symptoms is associated with longer life expectancy, with older children generally surviving two to seven years after the initial diagnosis. [22]

Krabbe disease occurs in about one in 100,000 births. [23] Because the disease is genetic, incidence rates vary widely from population to population. [21] The incidence rate is extremely low in Japan, with between 5 and 10 cases per 1,000,000 live births. In the United States, Krabbe disease occurs in approximately 1 out of every 100,000 live births. [24] Scandinavian countries report incidence rates of one in 50,000 births. [25] In certain communities Krabbe disease is much more frequent, such as the Druze community in Israel, which has an incidence rate of 6 out of every 1,000 live births. [24] This higher rate is thought to be due in part to a high frequency of consanguineous marriages. Almost 35% of all Druze marriages were found to be between first-cousin familial relations. [26] There have been no reported cases of Krabbe disease among the Jewish community. [24]

Time of onset also varies in frequency by location. Early infantile Krabbe Disease is the most common form of the disease overall, but Nordic communities tend to have even higher rates of early infantile onset Krabbe disease, while Southern European countries have higher incidences of late-onset cases. It is difficult to estimate the incidence of adult-onset Krabbe disease, due to discrepancies in classifying cases late-onset versus adult-onset. [24]

Society and culture

Former Buffalo Bills quarterback Jim Kelly has been a leader in gaining recognition and research funding for Krabbe disease following the diagnosis of his son, Hunter, in 1997. Hunter Kelly died of the disease on August 5, 2005, at the age of eight.[ citation needed ] They created Hunter's Hope - a foundation that seeks to advance Newborn Screening, research and treatments, and provides support to families of leukodystrophy children.[ citation needed ]

Family advocacy is a critical part of advancing newborn screening, and many Krabbe families have made significant advocacy progress in their states.[ citation needed ]

As an example, Cove Ellis is a child from Georgia, United States who was diagnosed with the disease in early 2016. Ellis' family, along with her community, has worked to raise awareness of the disease and helped pass "Cove's Law", which provides parents the option to have prenatal screening for the disease, which can, potentially, save the child from the morbidity and mortality of Krabbe disease. [27]

Other animals

Krabbe disease is found in mice [28] may also be found in cats [29] and in dogs, particularly the West Highland White Terriers and Cairn Terriers. [30] [31]

See also

Related Research Articles

<span class="mw-page-title-main">Adrenoleukodystrophy</span> Medical condition

Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by failure of peroxisomal fatty acid beta oxidation which results in the accumulation of very long chain fatty acids in tissues throughout the body. The most severely affected tissues are the myelin in the central nervous system, the adrenal cortex, and the Leydig cells in the testes. The long chain fatty acid buildup causes damage to the myelin sheath of the neurons of the brain, resulting in seizures and hyperactivity. Other symptoms include problems in speaking, listening, and understanding verbal instructions.

Canavan disease, or Canavan–Van Bogaert–Bertrand disease, is a rare and fatal autosomal recessive degenerative disease that causes progressive damage to nerve cells and loss of white matter in the brain. It is one of the most common degenerative cerebral diseases of infancy. It is caused by a deficiency of the enzyme aminoacylase 2, and is one of a group of genetic diseases referred to as leukodystrophies. It is characterized by degeneration of myelin in the phospholipid layer insulating the axon of a neuron and is associated with a gene located on human chromosome 17.

<span class="mw-page-title-main">Tay–Sachs disease</span> Human medical condition

Tay–Sachs disease is a genetic disorder that results in the destruction of nerve cells in the brain and spinal cord. The most common form is infantile Tay–Sachs disease, which becomes apparent around the age of three to six months of age, with the baby losing the ability to turn over, sit, or crawl. This is then followed by seizures, hearing loss, and inability to move, with death usually occurring by the age of three to five. Less commonly, the disease may occur later in childhood, adolescence, or adulthood. These forms tend to be less severe, but the juvenile form typically results in death by age 15.

<span class="mw-page-title-main">Lysosomal storage disease</span> Medical condition

Lysosomal storage diseases are a group of over 70 rare inherited metabolic disorders that result from defects in lysosomal function. Lysosomes are sacs of enzymes within cells that digest large molecules and pass the fragments on to other parts of the cell for recycling. This process requires several critical enzymes. If one of these enzymes is defective due to a mutation, the large molecules accumulate within the cell, eventually killing it.

<span class="mw-page-title-main">Adenosine deaminase deficiency</span> Medical condition

Adenosine deaminase deficiency is a metabolic disorder that causes immunodeficiency. It is caused by mutations in the ADA gene. It accounts for about 10–20% of all cases of autosomal recessive forms of severe combined immunodeficiency (SCID) after excluding disorders related to inbreeding.

<span class="mw-page-title-main">Alexander disease</span> Rare genetic disorder of the white matter of the brain

Alexander disease is a very rare autosomal dominant leukodystrophy, which are neurological conditions caused by anomalies in the myelin which protects nerve fibers in the brain. The most common type is the infantile form that usually begins during the first two years of life. Symptoms include mental and physical developmental delays, followed by the loss of developmental milestones, an abnormal increase in head size and seizures. The juvenile form of Alexander disease has an onset between the ages of 2 and 13 years. These children may have excessive vomiting, difficulty swallowing and speaking, poor coordination, and loss of motor control. Adult-onset forms of Alexander disease are less common. The symptoms sometimes mimic those of Parkinson’s disease or multiple sclerosis, or may present primarily as a psychiatric disorder.

<span class="mw-page-title-main">Glycogen storage disease type II</span> Medical condition

Glycogen storage disease type II, also called Pompe disease, and formerly known as GSD-IIa. It is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme. GSD-II and Danon disease are the only glycogen storage diseases with a defect in lysosomal metabolism, and Pompe disease was the first glycogen storage disease to be identified, in 1932 by the Dutch pathologist J. C. Pompe.

<span class="mw-page-title-main">Leukodystrophy</span> Group of disorders characterised by degeneration of white matter in the brain

Leukodystrophies are a group of, usually, inherited disorders, characterized by degeneration of the white matter in the brain. The word leukodystrophy comes from the Greek roots leuko, "white", dys, "abnormal" and troph, "growth". The leukodystrophies are caused by imperfect growth or development of the glial cells which produce the myelin sheath, the fatty insulating covering around nerve fibers. Leukodystrophies may be classified as hypomyelinating or demyelinating diseases, respectively, depending on whether the damage is present before birth or occurs after. Other demyelinating diseases are usually not congenital and have a toxic or autoimmune cause.

Metachromatic leukodystrophy (MLD) is a lysosomal storage disease which is commonly listed in the family of leukodystrophies as well as among the sphingolipidoses as it affects the metabolism of sphingolipids. Leukodystrophies affect the growth and/or development of myelin, the fatty covering which acts as an insulator around nerve fibers throughout the central and peripheral nervous systems. MLD involves cerebroside sulfate accumulation. Metachromatic leukodystrophy, like most enzyme deficiencies, has an autosomal recessive inheritance pattern.

<span class="mw-page-title-main">Sandhoff disease</span> Medical condition

Sandhoff disease is a lysosomal genetic, lipid storage disorder caused by the inherited deficiency to create functional beta-hexosaminidases A and B. These catabolic enzymes are needed to degrade the neuronal membrane components, ganglioside GM2, its derivative GA2, the glycolipid globoside in visceral tissues, and some oligosaccharides. Accumulation of these metabolites leads to a progressive destruction of the central nervous system and eventually to death. The rare autosomal recessive neurodegenerative disorder is clinically almost indistinguishable from Tay–Sachs disease, another genetic disorder that disrupts beta-hexosaminidases A and S. There are three subsets of Sandhoff disease based on when first symptoms appear: classic infantile, juvenile and adult late onset.

A lipid storage disorder is any one of a group of inherited metabolic disorders in which harmful amounts of fats or lipids accumulate in some body cells and tissues. People with these disorders either do not produce enough of one of the enzymes needed to metabolize and break down lipids or, they produce enzymes that do not work properly. Over time, the buildup of fats may cause permanent cellular and tissue damage, particularly in the brain, peripheral nervous system, liver, spleen, and bone marrow.

<span class="mw-page-title-main">Sphingolipidoses</span> Medical condition

Sphingolipidoses are a class of lipid storage disorders or degenerative storage disorders caused by deficiency of an enzyme that is required for the catabolism of lipids that contain ceramide, also relating to sphingolipid metabolism. The main members of this group are Niemann–Pick disease, Fabry disease, Krabbe disease, Gaucher disease, Tay–Sachs disease and metachromatic leukodystrophy. They are generally inherited in an autosomal recessive fashion, but notably Fabry disease is X-linked recessive. Taken together, sphingolipidoses have an incidence of approximately 1 in 10,000, but substantially more in certain populations such as Ashkenazi Jews. Enzyme replacement therapy is available to treat mainly Fabry disease and Gaucher disease, and people with these types of sphingolipidoses may live well into adulthood. The other types are generally fatal by age 1 to 5 years for infantile forms, but progression may be mild for juvenile- or adult-onset forms.

Galactosylceramidase, EC 3.2.1.46, is an enzyme that removes galactose from ceramide derivatives (galactosylceramides) by catalysing the hydrolysis of galactose ester bonds of galactosylceramide, galactosylsphingosine, lactosylceramide, and monogalactosyldiglyceride.

<span class="mw-page-title-main">Leukoencephalopathy with vanishing white matter</span> Neurological disease

Leukoencephalopathy with vanishing white matter is an autosomal recessive neurological disease. The cause of the disease are mutations in any of the 5 genes encoding subunits of the translation initiation factor eIF2B: EIF2B1, EIF2B2, EIF2B3, EIF2B4, or EIF2B5. The disease belongs to a family of conditions called the Leukodystrophies.

In molecular biology, glycoside hydrolase family 59 is a family of glycoside hydrolases.

<span class="mw-page-title-main">Hereditary diffuse leukoencephalopathy with spheroids</span> Medical condition

Hereditary diffuse leukoencephalopathy with spheroids (HDLS) is a rare adult onset autosomal dominant disorder characterized by cerebral white matter degeneration with demyelination and axonal spheroids leading to progressive cognitive and motor dysfunction. Spheroids are axonal swellings with discontinuous or absence of myelin sheaths. It is believed that the disease arises from primary microglial dysfunction that leads to secondary disruption of axonal integrity, neuroaxonal damage, and focal axonal spheroids leading to demyelination. Spheroids in HDLS resemble to some extent those produced by shear stress in a closed head injury with damage to axons, causing them to swell due to blockage of axoplasmic transport. In addition to trauma, axonal spheroids can be found in aged brain, stroke, and in other degenerative diseases. In HDLS, it is uncertain whether demyelination occurs prior to the axonal spheroids or what triggers neurodegeneration after apparently normal brain and white matter development, although genetic deficits suggest that demyelination and axonal pathology may be secondary to microglial dysfunction. The clinical syndrome in patients with HDLS is not specific and it can be mistaken for Alzheimer's disease, frontotemporal dementia, atypical Parkinsonism, multiple sclerosis, or corticobasal degeneration.

Maria Luisa Escolar is a pediatrician, clinical professor, and researcher who specializes in pediatric neurodevelopmental disabilities. She is Founder and Director of the Program for the Study of Neurodevelopment in Rare Disorders at Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center. Escolar is nationally and internationally known for her research and clinical care of children with leukodystrophies, lysosomal storage diseases, and other inherited metabolic diseases.

<span class="mw-page-title-main">Spongy degeneration of the central nervous system</span> Neurodegenerative disorder

Spongy degeneration of the central nervous system, also known as Canavan's disease, Van Bogaert-Bertrand type or Aspartoacylase (AspA) deficiency, is a rare autosomal recessive neurodegenerative disorder. It belongs to a group of genetic disorders known as leukodystrophies, where the growth and maintenance of myelin sheath in the central nervous system (CNS) are impaired. There are three types of spongy degeneration: infantile, congenital and juvenile, with juvenile being the most severe type. Common symptoms in infants include lack of motor skills, weak muscle tone, and macrocephaly. It may also be accompanied by difficulties in feeding and swallowing, seizures and sleep disturbances. Affected children typically die before the age of 10, but life expectancy can vary.

<span class="mw-page-title-main">Autosomal dominant leukodystrophy with autonomic disease</span> Medical condition

Autosomal dominant leukodystrophy with autonomic disease is a rare neurological condition of genetic origin which is characterized by gradual demyelination of the central nervous system which results in various impairments, including ataxia, mild cognitive disability and autonomic dysfunction. It is part of a group of disorders called "leukodystrophies".

References

  1. 1 2 3 4 5 Langan, Thomas J (23 November 2016). "Krabbe disease". UpToDate . Retrieved 18 October 2018.
  2. 1 2 Duffner, Patricia K.; Barczykowski, Amy; Jalal, Kabir; Yan, Li; Kay, Denise M.; Carter, Randy L. (September 2011). "Early Infantile Krabbe Disease: Results of the World-Wide Krabbe Registry". Pediatric Neurology. 45 (3): 141–148. doi:10.1016/j.pediatrneurol.2011.05.007. PMID   21824559.
  3. ↑ Li, Y; Sands, MS (November 2014). "Experimental therapies in the murine model of globoid cell leukodystrophy". Pediatric Neurology (Review). 51 (5): 600–6. doi:10.1016/j.pediatrneurol.2014.08.003. PMC   4252788 . PMID   25240259.
  4. ↑ synd/1457 at Who Named It?
  5. 1 2 3 4 5 Orsini, Joseph J.; Escolar, Maria L.; Wasserstein, Melissa P.; Caggana, Michele (1993), Adam, Margaret P.; Ardinger, Holly H.; Pagon, Roberta A.; Wallace, Stephanie E. (eds.), "Krabbe Disease", GeneReviews®, University of Washington, Seattle, PMID   20301416 , retrieved 2019-11-25
  6. ↑ Hussain, S. A.; Zimmerman, H. H.; Abdul-Rahman, O. A.; Hussaini, S. M.; Parker, C. C.; Khan, M. (May 2011). "Optic Nerve Enlargement in Krabbe Disease: A Pathophysiologic and Clinical Perspective". Journal of Child Neurology. 26 (5): 642–644. doi:10.1177/0883073810387929. PMID   21285037. S2CID   22242663.
  7. ↑ Cannizzaro, L.A. (1994). "Regional mapping of the human galactocerebrosidase gene (GALC) to 14q31 by in situ hybridization". Cytogenetic and Genome Research. 66 (4): 244–245. doi:10.1159/000133703. PMID   8162701.
  8. ↑ "Krabbe disease". National Institutes of Health.
  9. ↑ Kohlschütter, A (2013). "Lysosomal leukodystrophies". Pediatric Neurology Part III. Handbook of Clinical Neurology. Vol. 113. pp. 1611–18. doi:10.1016/B978-0-444-59565-2.00029-0. ISBN   9780444595652. PMID   23622382.
  10. ↑ Orsini, Joseph J.; Kay, Denise M.; Saavedra-Matiz, Carlos A.; Wenger, David A.; Duffner, Patricia K.; Erbe, Richard W.; Biski, Chad; Martin, Monica; Krein, Lea M.; Nichols, Matthew; Kurtzberg, Joanne (2016-03-01). "Newborn screening for Krabbe disease in New York State: the first eight years' experience". Genetics in Medicine. 18 (3): 239–248. doi: 10.1038/gim.2015.211 . ISSN   1530-0366. PMID   26795590.
  11. ↑ Escolar, ML; Kiely, BT; Shawgo, E; Hong, X; Gelb, MH; Orsini, JJ; Matern, D; Poe, MD (July 2017). "Psychosine, a marker of Krabbe phenotype and treatment effect". Molecular Genetics and Metabolism. 121 (3): 271–278. doi:10.1016/j.ymgme.2017.05.015. ISSN   1096-7192. PMC   5548593 . PMID   28579020.
  12. ↑ Shah, Samir S.; Ebberson, Jessica; Kestenbaum, Lori A.; Hodinka, Richard L.; Zorc, Joseph J. (January 2011). "Age-Specific Reference Values for Cerebrospinal Fluid Protein Concentration in Neonates and Young Infants". Journal of Hospital Medicine. 6 (1): 22–27. doi:10.1002/jhm.711. ISSN   1553-5592. PMC   2978786 . PMID   20629018.
  13. ↑ Duffner, Patricia K.; Caggana, Michele; Orsini, Joseph J.; Wenger, David A.; Patterson, Marc C.; Crosley, Carl J.; Kurtzberg, Joanne; Arnold, Georgianne L.; Escolar, Maria L. (2009-04-01). "Newborn Screening for Krabbe Disease: the New York State Model". Pediatric Neurology. 40 (4): 245–252. doi:10.1016/j.pediatrneurol.2008.11.010. PMID   19302934.
  14. ↑ (KRS 214.155)
  15. ↑ "unbs_state - Hunter's Hope Foundation". www.huntershope.org. Archived from the original on 2016-11-14. Retrieved 2016-11-14.
  16. ↑ Runevitch, Jennie. "Bryce's Battle: Family gets law change after deadly diagnosis". WTHR. Archived from the original on 2019-12-10. Retrieved 2019-03-25.
  17. ↑ Wright, Matthew D.; Poe, Michele D.; DeRenzo, Anthony; Haldal, Shilpa; Escolar, Maria L. (2017-09-26). "Developmental outcomes of cord blood transplantation for Krabbe disease: A 15-year study". Neurology. 89 (13): 1365–1372. doi:10.1212/WNL.0000000000004418. ISSN   1526-632X. PMC   5649761 . PMID   28855403.
  18. ↑ Laule, Cornelia; Vavasour, Irene M.; Shahinfard, Elham; Mädler, Burkhard; Zhang, Jing; Li, David K. B.; MacKay, Alex L.; Sirrs, Sandra M. (May 2018). "Hematopoietic Stem Cell Transplantation in Late-Onset Krabbe Disease: No Evidence of Worsening Demyelination and Axonal Loss 4 Years Post-allograft". Journal of Neuroimaging. 28 (3): 252–255. doi:10.1111/jon.12502. ISSN   1552-6569. PMID   29479774. S2CID   3533589.
  19. 1 2 3 4 5 Escolar, Maria L.; West, Tara; Dallavecchia, Alessandra; Poe, Michele D.; LaPoint, Kathleen (November 2016). "Clinical management of Krabbe disease". Journal of Neuroscience Research. 94 (11): 1118–1125. doi:10.1002/jnr.23891. ISSN   1097-4547. PMID   27638597. S2CID   34083553.
  20. ↑ "A Phase 1/2 Clinical Study of Intravenous Gene Transfer With an AAVrh10 Vector Expressing GALC in Krabbe Subjects Receiving Hematopoietic Stem Cell Transplantation (RESKUE)". clinicaltrials.gov. 5 May 2021.
  21. 1 2 Amin, Mutaz; Elsayad, Liena; Ahmed, Ammar Eltahir (2017). "Clinical and Genetic Characteristics of Leukodystrophies in Africa". Journal of Neurosciences in Rural Practice. 8 (S 01): S089–S093. doi: 10.4103/jnrp.jnrp_511_16 . PMC   5602269 . PMID   28936078.
  22. ↑ Mayo Clinic Staff (June 2018). "Krabbe Disease". Mayo Clinic.
  23. ↑ "Krabbe disease". Genetics Home Reference. United States National Library of Medicine. 2008-05-02. Retrieved 2008-05-07.
  24. 1 2 3 4 Matsuda, Junko; Suzuki, Kunihiko (2007), Barranger, John A.; Cabrera-Salazar, Mario A. (eds.), "Krabbe Disease (Globoid Cell Leukodystrophy)", Lysosomal Storage Disorders, Springer US, pp. 269–283, doi:10.1007/978-0-387-70909-3_18, ISBN   9780387709093
  25. ↑ Books.Google.com
  26. ↑ Zayed, Hatem (February 2015). "Krabbe Disease in the Arab World" (PDF). Journal of Pediatric Genetics. 4 (2146–4596): 001–008. doi:10.1055/s-0035-1554981. PMC   4906415 . PMID   27617109.
  27. ↑ Miller, Andy (March 18, 2017). "Georgia lawmakers considering bill on testing newborns for rare genetic disorder". Athens Banner-Herald. Athens Banner-Herald. Retrieved 25 March 2017.
  28. ↑ Suzuki, K. (July 1995). "The twitcher mouse: a model for Krabbe disease and for experimental therapies". Brain Pathology (Zurich, Switzerland). 5 (3): 249–258. doi: 10.1111/j.1750-3639.1995.tb00601.x . ISSN   1015-6305. PMID   8520724. S2CID   43425895.
  29. ↑ Salvadori C, Modenato M, Corlazzoli DS, Arispici M, Cantile C (May 2005). "Clinicopathological features of globoid cell leucodystrophy in cats". J. Comp. Pathol. 132 (4): 350–6. doi:10.1016/j.jcpa.2004.12.001. PMC   7172685 . PMID   15893994.
  30. ↑ NYtimes.com
  31. ↑ Capucchio MT, Prunotto M, Lotti D, Valazza A, Galloni M, Dore B, Pregel P, Amedeo S, Catalano D, Cornaglia E, Schiffer D (2008). "Krabbe's disease in two West Highland White terriers". Clin. Neuropathol. 27 (5): 295–301. doi:10.5414/npp27295. PMID   18808060.

This article incorporates public domain text from the United States National Library of Medicine and the National Institute of Neurological Disorders and Stroke.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.